Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
March 06 2023 - 6:40AM
Business Wire
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the
“Company,” “our,” “us,” or “we”), a biopharmaceutical company
focused on developing and commercializing novel therapies for
patients with severe diseases, announced that management will
participate in the Barclays Global Healthcare Conference held next
week, March 14-16, in Miami, Florida. Manmeet Soni, Reata’s
President, Chief Operating Officer, and Chief Financial Officer
will be participating in a fireside chat during the conference.
About Reata
Reata is a biopharmaceutical company committed to developing and
commercializing novel therapeutics for patients with serious or
life-threatening diseases with few or no approved therapies. We
focus on molecular pathways involved in the regulation of cellular
metabolism and inflammation. Reata developed the first and only
U.S. Food and Drug Administration approved product for Friedreich’s
ataxia. In addition, Reata has a robust pipeline and is developing
bardoxolone methyl (“bardoxolone”) for the treatment of patients
with various forms of chronic kidney disease and cemdomespib for
the treatment of patients with diabetic neuropathic pain.
Bardoxolone and cemdomespib are investigational drugs, and their
safety and efficacy have not been established by any regulatory
agency. For more information visit www.reatapharma.com and
follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release includes certain disclosures that contain
“forward-looking statements,” including, without limitation, our
plans and objectives for the commercialization of our products and
the timing thereof, our expectations regarding the size of the
patient population for our products, and our plans to research,
develop, and commercialize our other product candidates. You can
identify forward-looking statements because they contain words such
as “believes,” “will,” “may,” “aims,” “plans,” “model,” and
“expects.” Forward-looking statements are based on Reata’s current
expectations and assumptions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties,
risks, and changes in circumstances that may differ materially from
those contemplated by the forward-looking statements, which are
neither statements of historical fact nor guarantees or assurances
of future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include, but are not limited to, (i) the timing, costs,
conduct, and outcome of our clinical trials and future preclinical
studies and clinical trials, including the timing of the initiation
and availability of data from such trials; (ii) the timing and
likelihood of regulatory filings and approvals for our product
candidates; (iii) whether regulatory authorities determine that
additional trials or data are necessary in order to obtain approval
(iv) the potential market size and the size of the patient
population for our products and the market opportunities for our
products; (v) our ability to successfully build our commercial
infrastructure to manufacture, market and sell our products,
including the successful development and implementation of our
sales and marketing campaigns for our products; (vi) the ability of
our third-party suppliers and contract manufacturers to manufacture
our products at the required quality and quantities and in
compliance with applicable laws and regulations; and (vii) other
factors set forth in Reata’s filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the fiscal year ended December 31, 2022, under the caption “Risk
Factors.” The forward-looking statements speak only as of the date
made and, other than as required by law, we undertake no obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230306005321/en/
Reata Pharmaceuticals, Inc. (972) 865-2219
https://www.reatapharma.com/
Investor Relations & Media Relations: John Hunter
ir@reatapharma.com Wendy Segal media@reatapharma.com
https://www.reatapharma.com/contact-us/
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Jul 2023 to Jul 2024